Bobby Reddy, Jr., Co-Founder and CEO of Prenosis, has been named one of Crain’s Chicago Business 40 Under 40 for his visionary work in precision diagnostics and AI innovation. Under Bobby’s leadership, Prenosis has developed the Sepsis ImmunoScore™, the first FDA-authorized AI tool for sepsis risk prediction. The Sepsis ImmunoScore™ was built using Prenosis’ Immunix™ platform, which enables precision medicine in acute care.
“My core mission is to see things differently. To come in and see the individual patient, see individual biology,” said Reddy in the Crain’s article honoring him.
Bobby’s recognition by Crain’s Chicago Business is a testament not only to his achievements but to Prenosis’ mission of revolutionizing patient care through AI-driven diagnostics. We’re proud Crain’s is sharing Bobby’s story–and our story–to its readership, including over 200,000 business leaders and healthcare executives. Read more in Crain’s feature here (subscription required).